書誌事項
- タイトル別名
-
- A study of doripenem efficacy and safety in internal medicine
この論文をさがす
抄録
We conducted a late phase II study of doripenem (DRPM), a new carbapenem antibiotic for injection, in internal medicine.<BR>1. Clinical efficacy<BR>DRPM was administered at a dose of 250mg b.i.d., 250mg t.i.d., or 500mg b.i.d. for 3 to 14 days in patients with chronic respiratory tract infection, pneumonia, pulmonary suppuration, pyothorax, peritonsillar abscess, and cholecystitis. Overall efficacy was 87.6%(92/105). By disease, efficacy for patients with secondary infections associated with chronic respiratory disease was 93.1%(27/29) and for those with pneumonia, etc., 84.9%(62/73). A clinical efficacy evaluation of “effective” or “highly effective” was obtained in two patients with acute upper respiratory tract infection and in one with biliary tract infection.<BR>2. Bacteriological effect<BR>Bacterial eradication was observed in all 36 patients in whom changes in bacterial count from the baseline were investigated. Bacterial eradication was 100.0%.<BR>3. Safety<BR>Nonlaboratory adverse drug reactions occurred in two of 108 patients (1.9%) and laboratory adverse drug reactions in 32 of 106 patients (30.2%).<BR>These results suggest that DRPM at a dose of 250mg b.i.d., 250mg t.i.d., or 500mg b.i.d. has sufficient therapeutic effect on patients with infection in internal medicine.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 53 (Supplement1), 157-168, 2005
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206290342656
-
- NII論文ID
- 10016601170
- 130004102728
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可